Accelerate Diagnostics (NASDAQ:AXDX) Releases Earnings Results, Beats Expectations By $0.13 EPS

Accelerate Diagnostics (NASDAQ:AXDX) released its earnings results on Thursday. The medical research company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.13, Zacks reports. The company had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $3.00 million.

Accelerate Diagnostics Price Performance

NASDAQ AXDX traded down $0.07 during trading hours on Friday, hitting $1.06. 156,774 shares of the company’s stock traded hands, compared to its average volume of 59,715. Accelerate Diagnostics has a 52-week low of $0.73 and a 52-week high of $2.09. The company has a market capitalization of $26.55 million, a PE ratio of -0.37 and a beta of 0.55. The firm’s 50-day moving average is $1.16 and its 200-day moving average is $1.45.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. StockNews.com assumed coverage on shares of Accelerate Diagnostics in a research note on Monday, March 17th. They set a “hold” rating for the company. BTIG Research raised shares of Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.